Achillion is handing out pink slips to 20 percent of its employees and initiating an operational restructuring plan. Source: BioSpace

GW Pharmaceuticals announced that its pipeline compound GWP42006 failed to meet its primary endpoint in a Phase IIa proof of concept study for patients with focal seizures. Source: BioSpace

Shares of Regeneron are down following reports of increased observations of known side effects from blockbuster drug Eylea were reported by providing doctors. Source: BioSpace

AbbVie and Neurocrine Biosciences’ Phase III ELARIS UF-1 clinical trial of elagolix for uterine fibroids hit its primary endpoint. Source: BioSpace

Johnson & Johnson is hoping its $100 million deal with Theravance will serve as a replacement for Remicade which lost patent protection. Source: BioSpace

Here is a look at the life science companies viewed as the most innovative in the world. Source: BioSpace

The U.S. Food and Drug Administration (FDA) granted San Diego-based Evofem Biosciences Fast Track designation for Amphora vaginal gel to prevent urogenital chlamydia infection in women. Source: BioSpace

A new chief executive officer and a fresh infusion of $50 million in Series C funding has given Bay Area ORIC Pharmaceuticals a shot in the arm as it continues…

The U.S. Food and Drug Administration (FDA) approved AstraZeneca’s Imfinzi to treat patients with unresectable Stage III non-small cell lung cancer (NSCLC). Source: BioSpace

Dynavax announced it has secured a $175 million non-dilutive term loan agreement to commercialize Heplisav-B. Source: BioSpace